Coronavirus: Vaccination

Department of Health and Social Care written question – answered at on 13 July 2021.

Alert me about debates like this

Photo of Navendu Mishra Navendu Mishra Labour, Stockport

To ask the Secretary of State for Health and Social Care, what guidance his Department provides to Novavax covid-19 vaccine trial participants who have been unblinded and received two vaccine doses under that trial over six months ago on whether they should receive an approved covid-19 vaccination.

Photo of Navendu Mishra Navendu Mishra Labour, Stockport

To ask the Secretary of State for Health and Social Care, what (a) advice and (b) support his Department is providing to Novavax covid-19 vaccine trial participants who have been unblinded but do not have access to their antibody test results and are unsure of their level of protection against the covid-19 virus.

Photo of Nadhim Zahawi Nadhim Zahawi Parliamentary Under-Secretary (Department for Business, Energy and Industrial Strategy), The Parliamentary Under-Secretary for Health and Social Care

Guidance has been provided to support vaccine trial participants who wished to be unblinded at a time when they became eligible for an approved COVID-19 vaccine. This suggests individuals should discuss with the principle investigator at the site in which the participant was recruited who are best placed to advise on the options following unblinding.

In general, participants who only received a placebo would be recommended to receive the deployed COVID-19 vaccine schedule. Those that received a full course of an active vaccine, would be advised that further doses of deployed vaccine were not advisable. Whilst antibody tests were performed in the study, the advice on further vaccination would be based on the record of the participant's previous doses in the trial.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.